Health Canada opened a public consultation on July 20, 2026, on a draft revised guide covering the quality of natural health products. The consultation closes to new input on September 20, 2026, giving stakeholders across the natural health product sector roughly two months to review the draft and submit feedback before Health Canada finalizes it.
The draft guide, now at Version 4.0, replaces the current guide (Version 3.1) that has been in place since 2015. It centres on the finished product specifications (FPS) that companies must develop and maintain for natural health products (NHPs), spanning everything from raw material characterization through to stability testing and product release.
For companies already holding a Natural Product Number (NPN) or Homeopathic Medicine Number (DIN-HM), the implications extend beyond new submissions to the maintenance of existing product licences.
What the Draft Guide Covers
The proposed guide addresses the full range of quality-related requirements for NHPs, from raw material sourcing and specification setting through to finished product testing and stability data. Health Canada has organized the document around several core themes, including the identity, quantity and potency of medicinal and non-medicinal ingredients, acceptable specification parameters, and the purity and stability evidence needed to demonstrate that a product consistently meets its quality claims.
A defining feature of the draft is how closely it ties specification setting to internationally recognized pharmacopoeial standards. Throughout the document, Health Canada references specific chapters and monographs from the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) as the basis for testing methods and acceptance criteria, covering areas such as elemental impurities, microbial contamination, residual solvents, and mycotoxins. This reflects a broader push toward harmonization in how NHP quality is assessed relative to other regulated health products.
Stability requirements also receive detailed treatment. Health Canada expects licence holders to support their proposed shelf life with stability data appropriate to the product’s dosage form, packaging, and storage conditions, including specific provisions for probiotics, enzymes, and products with in-use periods after opening. For companies that have historically relied on limited stability programs, this could represent a meaningful increase in testing obligations.
Scope and Affected Product Categories
The consultation applies broadly across the NHP category as defined under the Natural Health Products Regulations. This includes non-sterile NHPs such as vitamins, minerals, amino acids, essential fatty acids, and botanical remedies, as well as sterile NHPs, homeopathic medicines, and traditional medicines such as traditional Chinese medicines and Ayurvedic medicines. Any company that currently holds or intends to apply for an NPN or a DIN-HM should consider the guide relevant to its operations.
Importantly, the guide is not limited to new product submissions. Health Canada has indicated that the quality standards outlined in the document will also inform its expectations for products already on the market, including post-licensing changes. This means existing licence holders may need to review their current quality documentation and testing protocols against the proposed framework.
Timeline for Stakeholder Feedback
Health Canada has opened the consultation for a defined comment period, during which stakeholders can submit written feedback on the draft guide. The department has encouraged input from a wide range of participants, including industry associations, individual companies, testing laboratories, and consumer groups. Specific details on the submission deadline and the preferred format for comments are available on the Health Canada consultation page.
Following the close of the comment period, Health Canada will review submissions and determine whether revisions to the draft are warranted before issuing a final version. While no firm date has been set for the publication of the finalized guide, the department has signalled its intention to move forward in a timely manner.
What This Means for Your Business
For NHP companies operating in Canada, this draft consultation represents more than a documentation update. The proposed NHP quality expectations could directly affect how companies manage their supply chains, set ingredient specifications, conduct testing, and maintain their product licences over time. Companies that have operated with minimal quality documentation may find that the finalized guide raises the baseline significantly.
Manufacturers and importers should begin by comparing their current quality systems and submission dossiers against the standards outlined in the draft. Areas where gaps exist, particularly around stability data, specification setting, and raw material qualification, should be flagged for internal review. Taking this step now, during the consultation period, positions companies to respond proactively rather than reactively once the final guide takes effect.
This consultation period also offers companies a direct opportunity to shape the outcome. Submitting evidence-based comments to Health Canada before September 20, 2026, can influence how the final guide balances regulatory rigour with practical feasibility for industry. Companies with specific concerns about proposed testing thresholds or documentation requirements should take advantage of this window while it remains open.
Frequently Asked Questions
Does the draft guide apply only to new NHP submissions, or does it affect existing product licences?
This is a common point of confusion, given that many guidance documents focus primarily on the application stage. However, Health Canada has indicated that the quality standards in the draft guide will apply to both new submissions and products that already hold an NPN or DIN-HM. Existing licence holders should review their quality documentation against the proposed expectations to identify any gaps that may need to be addressed once the guide is finalized.
Will companies need to adopt specific pharmacopoeial standards under the new guide?
The draft guide references internationally recognized pharmacopoeias, including the USP and Ph. Eur., as the basis for many testing methods and acceptance criteria. While the guide does not appear to mandate a single pharmacopoeial standard exclusively, it does signal that Health Canada expects applicants to justify their chosen specifications with reference to recognized compendial sources. Companies using in-house or non-compendial methods should be prepared to provide additional supporting evidence for their approach.
How can companies submit feedback on the draft consultation, and what happens after the comment period closes?
Companies can submit written comments by email to Health Canada’s Natural and Non-prescription Health Products Directorate at nnhpd.consultation-dpsnso@hc-sc.gc.ca before the comment period closes on September 20, 2026. Referencing the line-numbered PDF version of the draft can make it easier to point to specific sections in a submission. After the comment period ends, Health Canada will review the feedback received and make further changes as appropriate before publishing a final version, which the department aims to release later this year. An appropriate transition period will follow before the guide takes effect.
Key Takeaways
- The consultation opened on July 20, 2026, and Health Canada will accept comments on the draft guide until September 20, 2026.
- The draft guide updates the 2015 quality guide and centres on the finished product specifications (FPS) companies must develop and maintain for NHPs.
- The guide addresses specification setting, stability testing, raw material qualification, and alignment with international pharmacopoeial standards including USP and Ph. Eur.
- All NHP categories under the Natural Health Products Regulations are potentially affected, including vitamins, herbals, probiotics, and homeopathic medicines.
- The guide applies to both new submissions and existing licence holders, who should proactively compare current documentation against the proposed framework.
- Health Canada aims to publish a final version later this year, followed by a transition period before the guide takes effect.
Moving Forward
This draft consultation marks a clear signal from Health Canada that quality standards for natural health products are evolving. Companies that engage with the proposed guide now, both by reviewing their own compliance posture and by participating in the consultation process, will be better positioned when the final version is published.
For organizations that need support assessing how the proposed NHP quality expectations align with their current practices, Quality Smart Solutions provides regulatory advisory services tailored to natural health product companies. To discuss how these proposed changes may affect your product portfolio, contact Quality Smart Solutions to speak with a regulatory specialist.
